Table 3 Treatments and follow-up duration in the TAK >40 and TAK ≤40 groups
Variable | TAK >40, n = 20 | TAK ≤40, n = 23 | P value |
|---|---|---|---|
Initial dose of prednisolone, mg/day (IQR) | 30 (15–40) | 40 (30–45) | 0.024* |
Initial dose of prednisolone, mg/day (IQR) | 0.55 (0.28–0.82) | 0.80 (0.59–0.94) | 0.048* |
Pulsed methylprednisolone as an initial therapy | 2 (10) | 7 (30) | 0.142 |
Methotrexate with prednisolone before relapses, n (%), mg/week (IQR) | 7 (35), 8 (6–8) | 9 (39), 10 (7–13) | 1.00 |
Cyclosporine with prednisolone before relapses, n (%), mg/day (IQR) | 1 (5), 150 | 4 (17), 160 (105–238) | 0.35 |
Tacrolimus with prednisolone before relapses, n (%), mg/day (IQR) | 1 (5), 3.0 | 1 (4), 0.5 | 1.00 |
Infliximab, n (%) | 0 (0) | 5 (22) | 0.051 |
Adalimumab, n (%) | 0 (0) | 1 (4) | 1.00 |
Tocilizumab, n (%) | 1 (5) | 1 (4) | 1.00 |
Reduction rate of prednisolone dose, mg/month (IQR) | 2.7 (2.3–3.0) | 2.8 (2.4–2.9) | 0.87 |
Dose of prednisolone at relapse, mg/day (IQR) | 10 (8–16) | 15 (11–20) | 0.11 |
Follow-up duration, months (IQR) | 70 (25–133) | 55 (28–115) | 0.94 |